Evidence map›Paper›PMID 33735814›Full record

ReviewCurrent opinion in chemical biology2021

Imaging-guided nanomedicine development.

Aurora Bernal, Claudia Calcagno, Willem J M Mulder, Carlos Pérez-Medina

Abstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Enzyme-activated probes in optical imaging: a focus on atherosclerosis.Dalton transactions (Cambridge, England : 2003) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aurora BernalCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Claudia CalcagnoBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Willem J M MulderBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Chemical Biology, Eindhoven University of Technology, Eindhoven, the Netherlands.
Carlos Pérez-MedinaCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: cperez@cnic.es.

Funding

Translational imaging and nanomedicine in inflammatory atherosclerosisP01HL131478 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Zahi A. Fayad · 2017 to 2026
$24.3M
Atherosclerosis in cocaine addiction: imaging risk with PET/MRR01DA049547 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nelly Alia-Klein, Zahi A. Fayad · 2022 to 2026
$3.9M
PET nanoreporter image-guided breast cancer therapyR01CA220234 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAYAD, ZAHI A., PÉREZ-MEDINA, CARLOS · 2018 to 2022
$3.6M
TRAF6 Nanoimmunotherapy to resolve plaque inflammationR01HL144072 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAYAD, ZAHI A. · 2018 to 2021
$3.3M
NCI NIH HHS R01 CA220234NHLBI NIH HHS P01 HL131478NHLBI NIH HHS R01 HL144072NIDA NIH HHS R01 DA049547
6 · The paper itself

Abstract

Nanomedicine research is an active field that produces thousands of studies every year. However, translation of nanotherapeutics to the clinic has yet to catch up with such a vast output. In recent years, the need to better understand nanomedicines' in vivo behavior has been identified as one of the major challenges for efficient clinical translation. In this context, noninvasive imaging offers attractive solutions to provide valuable information about nanomedicine biodistribution, pharmacokinetics, stability, or therapeutic efficacy. Here, we review the latest imaging approaches used in the development of therapeutic nanomedicines, discuss why these strategies bring added value along the translational pipeline, and give a perspective on future advances in the field.

Indexed as

AnimalsDrug CarriersHumansIndicators and ReagentsMagnetic Resonance ImagingMolecular Targeted TherapyNanomedicineNanoparticlesOptical ImagingTissue DistributionTomography, Emission-ComputedDrug CarriersIndicators and Reagents

Identifiers

PMID33735814
PMCPMC8384634

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.